# Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients

> **NCT00884039** · NA · TERMINATED · sponsor: **Cornea Research Foundation of America** · enrollment: 7 (actual)

## Conditions studied

- Transplant
- Intraocular Pressure

## Interventions

- **DRUG:** anecortave acetate
- **DRUG:** 30 mg anecortave acetate

## Key facts

- **NCT ID:** NCT00884039
- **Lead sponsor:** Cornea Research Foundation of America
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2010-08
- **Final completion:** 2010-09
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Preliminary data analysis showed insufficient efficacy to justify continuation.
- **Last updated:** 2018-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00884039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00884039, "Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00884039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*